Polynoma is a San Diego, California-based private immuno-oncology company, currently developing a novel polyvalent antigen therapy, seviprotimut-L, for the treatment of melanoma. The Company’s primary technology is based on the life’s work of renowned clinical Professor of Dermatology, the late Jean-Claude Bystryn.

Polynoma is currently running one of the world’s largest melanoma clinical trials, for seviprotimut-L in the indication of resected stage IIB-III melanoma.

Polynoma LLC is a U.S. company within Hong Kong-based CK Life Sciences Int’l (Holdings), Inc. CK Life Sciences is a listed company on The Stock Exchange of Hong Kong Limited (stock code: 0775) and is a subsidiary of CK Hutchison Holdings Limited. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, commercialization, marketing and sale of health and agriculture related products. For additional information, please visit www.ck-lifesciences.com.